Does Medicare Cover Mounjaro? 2026 Rules

Does Medicare cover Mounjaro? It can, but only in a narrow case. Medicare Part D may cover Mounjaro (tirzepatide) when a doctor prescribes it for type 2 diabetes and the drug is on that plan’s formulary. Medicare does not cover Mounjaro when the prescription is written only for weight loss. The diagnosis, the plan’s drug list, and any prior authorization decide the claim. Two neighbors can take the same weekly injection and get opposite answers at the pharmacy.

Talk with a Big 65 Medicare broker about your drug list before you enroll.

Does Medicare Cover Mounjaro for Type 2 Diabetes?

Mounjaro is not a Medicare Part B office drug in ordinary use. It is a prescription you pick up at a pharmacy, so drug coverage comes from Medicare Part D or from the drug benefit inside a Medicare Advantage plan. Original Medicare by itself does not include routine outpatient prescriptions.

The FDA label matters because Part D plans follow approved uses. Eli Lilly’s label, posted on DailyMed, says Mounjaro is a GIP and GLP-1 receptor agonist. It is indicated with diet and exercise to improve blood sugar in adults, and in children 10 and older, who have type 2 diabetes. The same label also lists a use to reduce major cardiovascular events in adults with type 2 diabetes who are at high risk. It is a once-weekly injection. Adults may be increased to a maximum of 15 mg.

That label is why a type 2 diabetes prescription can be a covered Part D drug. Congress.gov notes that, as of August 2024, Mounjaro was treated as a covered Part D drug for its approved diabetes use, along with Ozempic and Rybelsus. A covered-drug status is not the same as a promise that your plan covers it. Each plan builds its own formulary, tier, and rules.

If your doctor wrote the prescription for type 2 diabetes, ask three things before you assume the copay:

• Is Mounjaro on this plan’s formulary for 2026, and which tier is it on?
• Does the plan require prior authorization, step therapy, or a quantity limit?
• Which diagnosis will the pharmacy claim use, and does it match the label?

Prior authorization usually means the plan wants chart notes showing type 2 diabetes, not a verbal assurance at the counter. Step therapy can mean the plan wants you to try another diabetes drug first, such as metformin or a different GLP-1, unless your doctor documents why that drug failed or is unsafe. Quantity limits can block an early refill. GoodRx’s Medicare coverage notes say most plans put restrictions on Mounjaro, so a formulary hit is only the first step.

Why Weight-Loss Use Is a Different Medicare Answer

People often hear that Mounjaro and a weight-loss shot are “the same medicine.” The ingredient, tirzepatide, is the same. The product, the FDA use, and the Medicare rule are not. Zepbound is Lilly’s tirzepatide product approved for chronic weight management. Mounjaro is the diabetes product. A plan can cover one and deny the other.

Medicare’s own page on weight-loss drugs says Medicare began covering certain GLP-1 drugs for weight management through a separate program. The covered names on that page are Foundayo, Wegovy, and Zepbound, and Zepbound is limited to the KwikPen. Mounjaro is not on that list. Medicare.gov’s weight-loss drug page is the list to check, not a social post that treats every GLP-1 as interchangeable.

For decades, the Part D statute has kept drugs out of the benefit when they are prescribed only for weight loss, anorexia, or weight gain. CMS describes the newer Medicare GLP-1 Bridge as a short-term demonstration that sits outside normal Part D payment. It runs from July 1, 2026, through December 31, 2027, and it uses a central processor rather than your plan’s usual claim. The Bridge does not turn every GLP-1 into a weight-loss benefit, and it does not add Mounjaro to that list.

If weight loss is the reason for the prescription, read our separate note on the $50 Medicare weight-loss drug program and stop there. That page covers the Bridge. This page stays on Mounjaro. If the prescription is for Ozempic instead, use our guide to whether Medicare covers Ozempic. Ozempic is semaglutide, a different drug with its own label.

What You May Pay When a Plan Covers Mounjaro

There is no single Medicare price for Mounjaro. Lilly’s Colorado prescriber disclosure lists a wholesale acquisition cost of $1,079.77 for a pack of four pens, and that figure is the same across the 2.5 mg through 15 mg strengths on that sheet. Wholesale acquisition cost is the price Lilly lists to distributors. It is not your copay, and it is not what the plan pays after rebates. The sheet was sourced in January 2025, so treat it as a list-price benchmark, not a pharmacy quote.

Your cost follows the Part D stages once the drug is covered. Medicare.gov’s Part D cost page says the highest deductible a plan may charge in 2026 is $615, though some plans charge less or nothing. After the deductible, you generally pay about 25 percent coinsurance for covered drugs until your out-of-pocket spending hits the cap. In 2026 that cap is $2,100. After that, you pay nothing for covered Part D drugs for the rest of the year.

A rough walk-through shows why the cap matters more than the monthly sticker. If Mounjaro is covered and you fill it all year, list-price math is about $1,080 times 12, or roughly $13,000 before plan payments. You would not pay that full amount when the claim is covered. You might pay the deductible, then coinsurance, and then stop at $2,100 for all covered Part D drugs combined, not for Mounjaro alone. Other prescriptions count toward the same cap. Extra Help can lower costs further for people who qualify, but the dollar amounts depend on the subsidy level.

Two warnings belong next to any cost quote. If the plan denies the claim, the $2,100 cap does not cap a cash price. Denied drugs do not march you toward catastrophic coverage. Also, manufacturer savings cards generally exclude people with Medicare, Medicaid, Medigap, VA, or TRICARE. Lilly says those patients are not eligible for the Mounjaro Savings Program. Do not plan your budget around a coupon you cannot use.

The Medicare Prescription Payment Plan is different from a coupon. It can spread what you owe for covered Part D drugs across the calendar year. It does not lower the total, and it does not apply to plan premiums. It only helps if the drug is covered in the first place.

How Mounjaro Coverage Compares With Nearby Drugs

Use this table to separate products before you call a plan. It is not a promise that any plan covers a row. Formulary status still has to be checked for the contract you would join.

Product	Drug	Usual Medicare path	What to verify
Mounjaro	Tirzepatide	Part D may cover it for type 2 diabetes when it is on the formulary.	Diagnosis, tier, prior authorization, and step therapy.
Zepbound	Tirzepatide	Not the diabetes brand. Weight-management access, if any, follows the separate GLP-1 Bridge rules, and only some presentations are listed.	Whether your prescription is the KwikPen and whether you meet Bridge rules.
Ozempic	Semaglutide	Part D may cover it for type 2 diabetes. It is not Mounjaro.	A different formulary line, even at the same pharmacy.
Wegovy	Semaglutide	A weight-management product named on Medicare’s GLP-1 weight-loss list.	Bridge eligibility, not a Mounjaro prior authorization.

Prediabetes is a common sticking point. The Mounjaro label we cited is for type 2 diabetes, not for preventing diabetes. A plan can deny a claim coded only as prediabetes or obesity even when your doctor hopes the drug will help both. Sleep apnea is another search that gets mixed in. Do not assume a Mounjaro diabetes prior authorization covers a different diagnosis. Ask the plan to read the exact diagnosis on the prescription.

Part B is the other mix-up. Part B can cover some drugs given in a doctor’s office. Mounjaro is packaged for you, or a caregiver, to inject under the skin once a week at home. That is a pharmacy benefit question. If someone tells you “Medicare covers it under Part B,” ask which benefit and which bill type. A wrong answer here leads to a rejected claim and a surprise bill.

Check Your Plan Before You Fill or Switch

Coverage is a plan decision, not a national yes. During Medicare Open Enrollment, from October 15 through December 7, you can change Part D or Medicare Advantage drug coverage for a January 1 start. People with a Medicare Advantage plan may also use the Medicare Advantage Open Enrollment Period from January 1 through March 31. A new diagnosis midyear does not, by itself, create a special enrollment period. If you already have drug coverage, start with your current formulary and a coverage determination, not a plan switch you do not need.

Work through the check in this order:

1. Ask your prescriber which product and which diagnosis will be on the prescription, in writing.
2. Look up that exact drug on the plan’s 2026 formulary, or on Medicare Plan Finder, and note the tier.
3. Read the prior authorization and step-therapy notes, then ask the clinic who submits them.
4. Price a one-month fill and a full year at that pharmacy, including your other drugs, so you can see the $2,100 cap in context.
5. If the plan says no, request a coverage determination and read the denial for the reason code before you pay cash.

A spouse’s employer plan, VA benefits, or Extra Help can change the math. Those paths are outside a standard Part D copay. Bring the denial letter or the formulary page to the conversation so the review is about your drug, not a general GLP-1 article.

The Big 65 is an independent brokerage. We compare Medicare Advantage and Part D drug coverage, plus Medigap, and the plan premium is the same whether you enroll with us or with the carrier. For the wider map of drug stages, deductibles, and the out-of-pocket cap, read how Medicare Part D prescription drug plans work in 2026. If you are also sorting insulin, test strips, or pumps, our guide to Medicare coverage for diabetes supplies is the right next page. Supplies and Mounjaro are billed differently.

We do not offer every plan available in your area. Currently, we represent 10 organizations that offer 50 products in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options.

Ask The Big 65 to check Mounjaro against the plans you can join.

Frequently Asked Questions

Does Medicare cover Mounjaro for weight loss?

No. Medicare does not cover Mounjaro when it is prescribed only for weight loss. Weight-management access, when it exists, follows a different product list that names other drugs, including certain Zepbound and Wegovy presentations. Mounjaro remains a type 2 diabetes product for Part D purposes.

Will Medicare cover Mounjaro in 2026 for type 2 diabetes?

It may. In 2026, a Part D or Medicare Advantage drug plan can cover Mounjaro for an FDA-approved diabetes use if the drug is on that plan’s formulary and you meet prior authorization or step therapy. There is no national rule that every plan must list it.

How much does Mounjaro cost per month with Medicare?

There is no single monthly copay. Lilly’s listed wholesale price is $1,079.77 for four pens, but a covered fill follows your deductible, coinsurance, and the $2,100 out-of-pocket cap for 2026. If the plan denies the drug, that cap does not limit the cash price.

Is Mounjaro covered by Medicare Part B or Part D?

Look to Part D, or to the drug coverage inside a Medicare Advantage plan. Mounjaro is a pharmacy injection you use at home. Part B is not the usual benefit for this prescription, and Original Medicare alone does not pay retail pharmacy claims.

What diagnosis will cover Mounjaro?

The label supports use for type 2 diabetes, including a cardiovascular-risk use in certain adults who already have type 2 diabetes. Prediabetes or weight loss alone is not the same claim. Your prescriber must document the diagnosis the plan requires, and the plan can still apply step therapy.